



# MEDRAD® Stellant CT injection system

## with Workstation

An imaging system designed for reliability and ease-of-use

The MEDRAD® Stellant CT Injection System offers a scalable platform to provide clinicians with tools to help improve efficiency, compliance and patient care.



### Features

- + **Integrated saline test with real-time pressure monitoring**
- + **Multi-phase programming**
- + **Programmable pressure limit**
- + **Dual-flow capabilities for cardiac imaging and pulmonary angiography**



# Ultravist®

An iodine based non-ionic monomeric low osmolar extracellular X-ray contrast medium (LOCM)

Three different iodine concentrations to meet your clinical needs



Highest  
Canadian  
approved  
concentration  
of 370 mg I/mL

**Ultravist® 240**  
50 mL, 200 mL

**Ultravist® 300**  
50 mL, 100 mL,  
150 mL, 500 mL


**Ultravist® 370**  
50 mL, 100 mL,  
200 mL, 500 mL

# Ultravist®


A contrast media with reliable image quality  
and proven safety



**93.9%** of investigations rated image quality as “good” or “excellent”<sup>1</sup>



3:1 Iodine ratio, providing good radiographic contrast



Rapid renal elimination



**99.5%** of applications with none to mild adverse reactions

**Ultravist® balances osmolality, viscosity and iodine concentration to allow for consistent delivery of high-quality CT images**



**INDICATIONS AND CLINICAL USE:** ULTRAVIST® 240/300/370 Ultravist® (iopromide) in its three strengths, is indicated for intravascular use to provide diagnostic information in a number of radiographic contrast procedures. It is also indicated for the visualization of various body cavities, e.g., arthrography and hysterosalpingography. **Ultravist® 240:** Computed tomography (CT), Peripheral arteriography (bifemoral pelvis/leg), Phlebography of the extremities, Arthrography, Hysterosalpingography, Cerebral Arteriography. **Ultravist® 300:** Computed tomography (CT), Excretory urography, Pediatric excretory urography, Renal arteriography, Peripheral arteriography (bifemoral pelvis/leg), Cerebral arteriography, Phlebography of the extremities, Arthrography. **Ultravist® 370:** Computed tomography (CT), Excretory urography, Coronary arteriography, (including PTCA), with or without left ventriculography, Pediatric angiography, Arthrography \*For information on the concentrations and doses for the Pediatric Population see *Dosage and Administration and Use in Special Populations* in the Full Prescribing Information.

**IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS:** Ultravist® (iopromide) is not indicated for use in myelography, cerebral ventriculography, and cisternography. Ultravist® should not be administered to patients with known hypersensitivity to the drug, or with manifest hyperthyroidism.

**SELECTED WARNINGS AND PRECAUTIONS:** Life-threatening or fatal anaphylactoid reactions may occur during or after Ultravist® administration, particularly in patients with allergic disorders. Contrast media-induced nephrotoxicity, presenting as transient impairment of renal function, may occur after intravascular Ultravist® administration. Patients with pre-existing renal impairment, diabetes mellitus, sepsis, hypotension, dehydration, cardiovascular disease, elderly patients, and patients with multiple myeloma, hypertension, patients on medications which alter renal function and patients with hyperuricemia, are at increased risk of this condition. Hemodynamic disturbances including shock and cardiac arrest may occur during or shortly after administration of Ultravist®. Angiography may be associated with local and distal organ damage, ischemia, thromboembolism and organ failure. In angiographic procedures, consider the possibility of dislodging plaques or damaging or perforating the vessel wall with resultant pseudoaneurysms, hemorrhage at puncture site, dissection of coronary artery during catheter manipulations and contrast agent injection. The physicochemical properties of the contrast agent, the dose and the speed of injection can influence the reactions. Thyroid storm has occurred after the intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with autonomously functioning thyroid nodule. Evaluate the risk in such patients before use of any iodinated contrast agent. Administer iodinated contrast agents with extreme caution in patients with known or suspected pheochromocytoma. Inject the minimal amount of contrast necessary. Contrast agents may promote sickling in individuals who are homozygous for sickle cell disease when administered intravascularly.

**MOST COMMON ADVERSE REACTIONS:** The most frequently observed adverse drug reactions (>4%) in patients receiving Ultravist® are headache, nausea, and vasodilation.

Please consult the Product Monograph at [www.bayer.ca/ultravist](http://www.bayer.ca/ultravist) for important information relating to adverse reactions, drug interactions and dosing information.

**Reference:** 1. Palkowitsch PK, et al. Safety and tolerability of iopromide intravascular use: a pooled analysis of three non-interventional studies in 132,012 patients. *Acta Radiol* 2014;55(6):707–14.

# Consumables

## High-quality syringes to support reliable system performance

Our syringes are designed and tested as part of an inter-related system to ensure the fluid delivery performance with your MEDRAD® Stellant CT Injection System.



- ⊕ **100% inspection for particulates**
- ⊕ **Confirmed biological safety\***
- ⊕ **Dependable system performance**
- ⊕ **Automated precision crafting**



\* Bayer conducts analytical chemistry studies on finished products to ensure that our syringes fully meet medical biocompatibility requirements and do not contain any harmful substances.

# Consumables

Perform multiple scans with a single syringe kit  
for up to 12 hours

Bayer combines three safety features in one efficient multi-patient syringe system.

